Scholarlink

Objectives <p>This study aimed to evaluate preoperative MRI risk factors for metastatic disease in patients who underwent neoadjuvant chemoradiotherapy (nCRT) and curative surgery, followed or not by adjuvant chemotherapy (ChT).</p> Materials and methods <p>Single-center post hoc analysis of a randomized clinical trial data to evaluate the effect of adjuvant ChT in comparison to observation in patients with rectal cancer receiving nCRT and surgical resection. Preoperative MRI variables were retrospectively reviewed by three observers. Clinical, surgical, and pathological variables were included in univariate and multivariate analysis, and metastasis risk was assessed. A subgroup analysis was further performed to evaluate the effect of ChT on metastasis incidence in both good and poor responders to neoadjuvant treatment.</p> Results <p>A total of 132 patients (54% female, median age 55 years) were included. Poor mrTRG (HR = 2.53, 95% CI 1.32–5.65) and stage pIII disease (HR 1.94, 95% CI 1.09–3.45) were associated with increased metastatic risk. Although the rate of metastasis was lower in the treated group (9.1%) than in the control group (26.1%) among the patients who achieved a good response (mrTRG 1-2), the difference was not statistically significant (<i>p</i> = 0.19). The subgroup analysis revealed no difference in metastasis rates between patients with poor response receiving or not receiving adjuvant ChT.</p> Conclusion <p>Response assessed by mrTRG is a preoperative prognostic factor associated with increased metastasis-free survival. MRI restaging could not predict the clinical benefits of adjuvant oxaliplatin-based ChT.</p> Key Points <p><Emphasis Type="BoldItalic">Question</Emphasis> <i>To patients who have rectal cancer, the prediction of risk for metastatic disease during baseline staging to indicate systemic chemotherapy remains challenging</i>.</p> <p><Emphasis Type="BoldItalic">Findings</Emphasis> <i>MR-assessed poor tumor regression grade after neoadjuvant chemoradiotherapy (mrTRG3-5) and pathological postoperative nodal positivity are associated with increased metastatic risk</i>.</p> <p><Emphasis Type="BoldItalic">Clinical relevance</Emphasis> <i>The unpredictable response to neoadjuvant chemoradiotherapy is a significant driver of prognosis. The metastasis rates among good and poor responders receiving or not receiving adjuvant chemotherapy were similar. Challenges remain in selecting the population that will benefit from additional treatment</i>.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Preoperative MRI assessment of rectal cancer for predicting metastasis-free survival—a post hoc analysis of a randomized controlled clinical trial

  • 期刊论文

  • 发表日期：

    2025年10月29日

查看全文
  • Cinthia D. Ortega,
  • Renata Motta Grubert,
  • Thiago Menezes Baraviera,
  • Paulo Victor Alves Pinto,
  • Laís Fernanda Correia Pimentel,
  • Juliana Helena Manso Brandão,
  • Maria Ignez Freitas Braghiroli,
  • Camila Motta Venchiarutti Moniz,
  • Paulo M. Hoff,
  • Caio Sergio Rizkallah Nahas,
  • Carlos Frederico Sparapan Marques,
  • Jorge Sabbaga

摘要

Objectives

This study aimed to evaluate preoperative MRI risk factors for metastatic disease in patients who underwent neoadjuvant chemoradiotherapy (nCRT) and curative surgery, followed or not by adjuvant chemotherapy (ChT).

Materials and methods

Single-center post hoc analysis of a randomized clinical trial data to evaluate the effect of adjuvant ChT in comparison to observation in patients with rectal cancer receiving nCRT and surgical resection. Preoperative MRI variables were retrospectively reviewed by three observers. Clinical, surgical, and pathological variables were included in univariate and multivariate analysis, and metastasis risk was assessed. A subgroup analysis was further performed to evaluate the effect of ChT on metastasis incidence in both good and poor responders to neoadjuvant treatment.

Results

A total of 132 patients (54% female, median age 55 years) were included. Poor mrTRG (HR = 2.53, 95% CI 1.32–5.65) and stage pIII disease (HR 1.94, 95% CI 1.09–3.45) were associated with increased metastatic risk. Although the rate of metastasis was lower in the treated group (9.1%) than in the control group (26.1%) among the patients who achieved a good response (mrTRG 1-2), the difference was not statistically significant (p = 0.19). The subgroup analysis revealed no difference in metastasis rates between patients with poor response receiving or not receiving adjuvant ChT.

Conclusion

Response assessed by mrTRG is a preoperative prognostic factor associated with increased metastasis-free survival. MRI restaging could not predict the clinical benefits of adjuvant oxaliplatin-based ChT.

Key Points

Question To patients who have rectal cancer, the prediction of risk for metastatic disease during baseline staging to indicate systemic chemotherapy remains challenging.

Findings MR-assessed poor tumor regression grade after neoadjuvant chemoradiotherapy (mrTRG3-5) and pathological postoperative nodal positivity are associated with increased metastatic risk.

Clinical relevance The unpredictable response to neoadjuvant chemoradiotherapy is a significant driver of prognosis. The metastasis rates among good and poor responders receiving or not receiving adjuvant chemotherapy were similar. Challenges remain in selecting the population that will benefit from additional treatment.

Graphical Abstract